Literature DB >> 28939491

Fab antibody fragment-functionalized liposomes for specific targeting of antigen-positive cells.

Anna Ohradanova-Repic1, Eugénia Nogueira2, Ingrid Hartl3, Andreia C Gomes4, Ana Preto4, Eva Steinhuber3, Vanessa Mühlgrabner3, Marko Repic5, Mario Kuttke6, Alexander Zwirzitz3, Marek Prouza7, Miloslav Suchanek7, Gordana Wozniak-Knopp8, Vaclav Horejsi9, Gernot Schabbauer6, Artur Cavaco-Paulo10, Hannes Stockinger3.   

Abstract

Liposomes functionalized with monoclonal antibodies or their antigen-binding fragments have attracted much attention as specific drug delivery devices for treatment of various diseases including cancer. The conjugation of antibodies to liposomes is usually achieved by covalent coupling using cross-linkers in a reaction that might adversely affect the characteristics of the final product. Here we present an alternative strategy for liposome functionalization: we created a recombinant Fab antibody fragment genetically fused on its C-terminus to the hydrophobic peptide derived from pulmonary surfactant protein D, which became inserted into the liposomal bilayer during liposomal preparation and anchored the Fab onto the liposome surface. The Fab-conjugated liposomes specifically recognized antigen-positive cells and efficiently delivered their cargo, the Alexa Fluor 647 dye, into target cells in vitro and in vivo. In conclusion, our approach offers the potential for straightforward development of nanomedicines functionalized with an antibody of choice without the need of harmful cross-linkers.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Active targeting; Antibody engineering; Immunoliposome; Liposome functionalization; Recombinant Fab antibody fragment

Mesh:

Substances:

Year:  2017        PMID: 28939491     DOI: 10.1016/j.nano.2017.09.003

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  7 in total

1.  Quercetin-biapigenin nanoparticles are effective to penetrate the blood-brain barrier.

Authors:  Ana Isabel Oliveira; Cláudia Pinho; Bruno Sarmento; Alberto C P Dias
Journal:  Drug Deliv Transl Res       Date:  2021-03-11       Impact factor: 4.617

Review 2.  Invasome: A Novel Nanocarrier for Transdermal Drug Delivery.

Authors:  Soraya Babaie; Azizeh Rahmani Del Bakhshayesh; Ji Won Ha; Hamed Hamishehkar; Ki Hyun Kim
Journal:  Nanomaterials (Basel)       Date:  2020-02-17       Impact factor: 5.076

Review 3.  Active Cellular and Subcellular Targeting of Nanoparticles for Drug Delivery.

Authors:  Okhil K Nag; James B Delehanty
Journal:  Pharmaceutics       Date:  2019-10-18       Impact factor: 6.321

4.  Blockade of TMPRSS2-mediated priming of SARS-CoV-2 by lactoferricin.

Authors:  Anna Ohradanova-Repic; Rostislav Skrabana; Laura Gebetsberger; Gabor Tajti; Peter Baráth; Gabriela Ondrovičová; Romana Praženicová; Nikola Jantova; Patricia Hrasnova; Hannes Stockinger; Vladimir Leksa
Journal:  Front Immunol       Date:  2022-08-23       Impact factor: 8.786

Review 5.  Therapy of infected wounds: overcoming clinical challenges by advanced drug delivery systems.

Authors:  Pia Kaiser; Jana Wächter; Maike Windbergs
Journal:  Drug Deliv Transl Res       Date:  2021-02-20       Impact factor: 4.617

Review 6.  Bio-Nanocarriers for Lung Cancer Management: Befriending the Barriers.

Authors:  Shruti Rawal; Mayur Patel
Journal:  Nanomicro Lett       Date:  2021-06-12

Review 7.  Development of therapeutic antibodies for the treatment of diseases.

Authors:  Ruei-Min Lu; Yu-Chyi Hwang; I-Ju Liu; Chi-Chiu Lee; Han-Zen Tsai; Hsin-Jung Li; Han-Chung Wu
Journal:  J Biomed Sci       Date:  2020-01-02       Impact factor: 8.410

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.